ப்ரிந்ஸிபல் புலனாய்வாளர் மைக்கேல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
ENGLEWOOD, Colo., May 10, 2021 /PRNewswire/ Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board (IRB) approval to commence enrollment in its AP-018 Phase I study using inhaled Ampion™ with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long (or long-haul) COVID, or Post-Acute Sequelae of SARS-CoV-2.
This trial is both needed and exciting in that it addresses a major current and expected ongoing unmet medical need among the estimated 3 to 10 million individuals currently suffering from long COVID, said Michael Macaluso, President and CEO of Ampio. ....

United States , Katie Kennedy , Michael Macaluso , Joe Hassett , Exchange Commission , Ampio Pharmaceuticals , Ampio Pharmaceuticals Inc , Prnewswire Ampio Pharmaceuticals , Investigational Review Board , Post Acute Sequelae , Principal Investigator Michael , Intravenous Nutritional Services , Strata Integrated Wellness , Principal Investigator , Michael Barber , Placebo Controlled Phasei Study , Prolonged Respiratory Symptoms , Private Securities Litigation Reform Act , Biological License Application , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , கேடீ கெந்நெடீ , மைக்கேல் மக்ளுஸோ , ஓஹோ ஹாசெட் , பரிமாற்றம் தரகு , ப்ரிந்ஸிபல் புலனாய்வாளர் மைக்கேல் ,